Table 3.
Outcomes of the Patients according to the treatment assignment.
| Variable | Total n = 197 |
Baricitinib + Dexamethasone n = 123 |
Dexamethasone n = 74 |
P value |
|---|---|---|---|---|
| Length of stay, median of days (IQR) | 7.0 (4.0–13.0) | 8.0 (5.0–13.0) | 6.0 (3.0–12.25) | .01 |
| Intensive care unit admission, n (%) | 85 (42.9) | 59 (47.6) | 26 (35.1) | .05 |
| Progression to high flow, n (%) | 31 (15.7) | 26 (21.1) | 5 (6.7) | <.01 |
| Progression to invasive mechanical ventilation, n (%) | 25 (12.6) | 15 (12.1) | 10 (13.5) | .94 |
| Thrombotic events, n (%) | 5 (2.5) | 4 (3.2) | 1 (1.4) | .39 |
| Pulmonary embolism, n (%) | 4 (2.0) | 3 (2.4) | 1 (1.4) | .64 |
| Deep venous thrombosis, n (%) | 1 (.8) | 0 | 1 (.5) | .64 |
| No. patients with breakthrough infections, n (%) | 39 (19.7) | 19 (15.3) | 20 (27.0) | .03 |
| Bacterial pneumonia, n (%) | 31 (15.7) | 17 (13.7) | 14 (18.9) | .21 |
| Urinary tract infection, n (%) | 11 (5.6) | 6 (4.8) | 5 (6.8) | .39 |
| Catheter-related bloodstream infection, n (%) | 14 (7.1) | 12 (9.7) | 2 (2.7) | .05 |
| Others, n (%) | 7 (3.5) | 0 | 7 (9.5) | <.01 |
| No. days since baricitinib initiation until breakthrough infection, median (IQR) | 10.0 (4.0–10.0) | 10.0 (4.0–10.0) | – | – |
| No. days since dexamethasone initiation until breakthrough infection, median (IQR) | 10.0 (6.0–10.0) | 10.0 (7.0–10.0) | 7.0 (4.0–13.0) | .51 |
| Acute kidney injury, n (%) | 30 (15.2) | 17 (13.7) | 13 (17.6) | .29 |
| Kidney replacement therapy, n (%) | 20 (10.1) | 9 (7.3) | 11 (14.9) | .07 |
| 30-day mortality, n (%) | 55 (27.9) | 25 (20.3) | 30 (40.5) | <.01 |